1998
DOI: 10.1139/y98-073
|View full text |Cite
|
Sign up to set email alerts
|

Positive inotropy due to lowering cyclic GMP is also mediated by increases in cyclic AMP in control and hypertrophic hearts

Abstract: The aim of the current study was to determine if lowering myocardial cyclic GMP by guanylate cyclase inhibition would add independently to the positive inotropic effects caused by raising cyclic AMP and if these effects are modified in left ventricular hypertrophy (LVH) produced by aortic valve plication. Isoproterenol (ISO) (0.1 mg x kg(-1) x min(-1)) was infused into a branch of the left anterior descending coronary artery of seven control and eight hypertrophy open-chest anesthetized dogs. After 10 min, sim… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
14
0

Year Published

1999
1999
2013
2013

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 11 publications
(14 citation statements)
references
References 23 publications
0
14
0
Order By: Relevance
“…Previous work has demonstrated that the effects of cGMP are not changed by the activity of L‐type calcium channels in cardiac myocytes, 18,25 although calcium currents could be altered 26 . Cyclic GMP also antagonizes the positive inotropic effects of catecholamines and cAMP 12,13,27 . Cyclic GMP can change cAMP levels through cGMP‐regulated cAMP phosphodiesterases 12 .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Previous work has demonstrated that the effects of cGMP are not changed by the activity of L‐type calcium channels in cardiac myocytes, 18,25 although calcium currents could be altered 26 . Cyclic GMP also antagonizes the positive inotropic effects of catecholamines and cAMP 12,13,27 . Cyclic GMP can change cAMP levels through cGMP‐regulated cAMP phosphodiesterases 12 .…”
Section: Discussionmentioning
confidence: 99%
“…Other studies have shown that blocking this pathway significantly diminishes the effects of cGMP 6,7,9–11 . Cyclic GMP also interacts with the second messenger cAMP through cGMP‐regulated cAMP phosphodiesterases 1,12 . However, these two second messengers can also interact at the level of their respective protein kinases 1,10 , 11,13 .…”
Section: Introductionmentioning
confidence: 99%
“…In contrast, MB acts through a reduction in intracellular cGMP . Because of its unique mechanism of action, MB has been investigated across different clinical scenarios involving treatment‐refractory hypotension associated with low SVR such as that occurring during and after cardiopulmonary bypass, sepsis, and liver transplantation [, ]. In liver transplantation, however, there is significant controversy concerning the role of NO in the protection of the liver graft and concerning the benefits of MB during orthotopic liver transplantation (OLT) .…”
Section: Introductionmentioning
confidence: 99%
“… 4,12,14 There is good evidence that the second messenger cGMP may work through a cGMP‐stimulated protein kinase 14 . It has also been demonstrated that alterations in cGMP can affect the level of cAMP in the heart and myocytes 11,32 . This may explain some of the reported increases in function with low doses of NO 4 .…”
Section: Discussionmentioning
confidence: 99%
“…The nitric oxide (NO)-cGMP signal transduction system reduces heart and cardiac myocyte function and metabolism. 4,10,11 It also causes vascular smooth muscle dilatation. 12,13 Nitric oxide primarily acts through increases in cGMP, which can affect myocyte calcium levels, the degree of protein phosphorylation and cAMP levels.…”
Section: Introductionmentioning
confidence: 99%